A Multicenter, Open-Label, Two-Stage, Phase II Study Of PS-341 (LDP-341, NSC 681239) In Patients With Unresectable Or Metastatic Gastric Adenocarcinoma.
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2012
At a glance
- Drugs Bortezomib (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 13 Feb 2012 Actual end date (1 Apr 2005) added as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Aug 2007 Status changed from suspended to in progress.